EXHIBIT 10.76 ADDITIONAL FUNDING AGREEMENT This Agreement (this "AGREEMENT") is dated as of May 13, 2003, by and among Viragen, Inc. (the "COMPANY") and Bristol Investment Fund, Ltd. (the "PURCHASER"). WHEREAS, the Company and certain other purchasers...Additional Funding Agreement • May 30th, 2003 • Viragen Inc • Biological products, (no disgnostic substances)
ADDITIONAL FUNDING AGREEMENTAdditional Funding Agreement • October 10th, 2008 • Oxigene Inc • Biological products, (no disgnostic substances) • Delaware
This ADDITIONAL FUNDING AGREEMENT (this “Agreement”) is entered into as of October 1, 2008, by and among OXiGENE, INC., a Delaware corporation (the “Company”), SYMPHONY ViDA HOLDINGS LLC, a Delaware limited liability company (“Holdings”), SYMPHONY ViDA INVESTORS LLC, a Delaware limited liability company (“Investors”), and SYMPHONY ViDA, INC., a Delaware corporation (the “Symphony Collaboration”).
ADDITIONAL FUNDING AGREEMENTAdditional Funding Agreement • May 7th, 2003 • Avi Biopharma Inc • Pharmaceutical preparations
This Agreement (this “Agreement”) is dated as of May 6, 2003, by and among AVI BioPharma, Inc., an Oregon corporation (the “Company”) and Riverview Group, LLC, Cranshire Capital L.P., Smithfield Fiduciary LLC, Omicron Master Trust, The Tail Wind Fund Limited, Solomon Strategic Holdings, Inc., MRT, L.P. and Rodman & Renshaw, Inc. (collectively referred to as the “Purchasers”).
ADDITIONAL FUNDING AGREEMENTAdditional Funding Agreement • May 22nd, 2003 • Path 1 Network Technologies Inc • Communications equipment, nec
This Agreement (this “Agreement”) is dated as of May 12, 2003, by and among Path 1 Network Technologies, Inc. (the “Company”) and Palisades Master Fund L.P., Crescent International Ltd., Alpha Capital AG and Barucha LTD, as defined on the signature page hereto (collectively referred to as the “Purchasers”).
